An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity

Abstract

The recent development of successful CAR (chimeric antigen receptor) Tcell therapies has been accompanied by a need to better control potentially fatal toxicities that can arise from adverse immune reactions. Here we present a ligand-controlled CAR system, based on the IKZF3 ZF2 β-hairpin IMiD-inducible degron, which allows for the reversible control of expression levels of type I membrane proteins, including CARs. Testing this system in an established mouse xenotransplantation model for acute lymphoblastic leukemia, we validate the ability of the CAR19-degron to target and kill CD19-positive cells displaying complete control/clearance of the tumor. We also demonstrate that the activity of CAR19-degron can be regulated invivo when dosing a US Food and Drug Administration-approved drug, lenalidomide.